PF-07265807 Clinical Trials

Size	Price	Qty
5mg	USD 197
25mg	USD 497

Clinical Trials

The clinical development landscape for PF-07265807 includes a clinical trial sponsored by Pfizer to evaluate the safety, tolerability, pharmacokinetics, and dosing of the agent in adult patients with neoplasm metastasis. Although designed as a Phase 1 open-label study for advanced metastatic malignancies, recruitment was ultimately terminated. Consequently, available human clinical data for PF-07265807 remain restricted to this early-phase evaluation, underscoring a continued reliance on preclinical findings.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04458259	TERMINATED	Neoplasm Metastasis	Pfizer	2020-09-24	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-04)

Check the PF-07265807 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

PF-07265807 acts as a dual receptor tyrosine kinase inhibitor targeting AXL and MER, thereby blocking downstream oncogenic signaling cascades and enhancing the capacity of dendritic cells to cross-prime CD8+ cytotoxic T lymphocytes. This simultaneous inhibition of immunosuppressive signaling and stimulation of anti-tumor immunity suppresses tumor cell proliferation and dissemination, highlighting its therapeutic potential against neoplasm metastasis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).